I. Jung Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
I. Jung Feng has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Yow-Ling Shiue
Institute of Precision Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan
4 shared publications - Chia-Yi Hou
Department of Clinical Pathology, Chi-Mei Medical Center, Liouying, Tainan 736402, Taiwan
2 shared publications - Chien-Cheng Huang
Department of Emergency Medicine, Chi Mei Medical Center, Tainan, Taiwan
2 shared publications - Chien-Chin Hsu
Department of Emergency Medicine, Chi-Mei Medical Center, Tainan, Taiwan
2 shared publications - Chien-Yuan Huang
Division of Occupational Medicine, Chi-Mei Medical Center, Liouying, Tainan 736402, Taiwan
2 shared publications - Jhi-Joung Wang
Department of Anesthesiology, Chi Mei Medical Center, Tainan, Taiwan
2 shared publications
Latest Publications
- Open Access
- 8 February 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70110
Advances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review
Chronic viral hepatitis, predominantly caused by HBV and HCV infections, remains a major global health burden and a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver‐related mortality. Achieving the World Health Organisation (WHO) target of diagnosing 90% of HBV and HCV infections by 2030 necessitates a fundamental transition from centralised laboratory‐based testing towards rapid, accessible, and decentralised diagnostic solutions. This review provides a comprehensive and critical assessment of the current diagnostic landscape for viral hepatitis, spanning established commercial assays and emerging nucleic acid testing (NAT) technologies. We systematically examine recent advances in biosensor‐enabled diagnostics, with particular emphasis on the integration of isothermal amplification and CRISPR‐based molecular recognition into electrochemical and field‐effect transistor (FET) platforms. These electronic sensing technologies enable label‐free signal transduction, scalable miniaturisation, and seamless integration with point‐of‐care (POC) workflows, thereby addressing key limitations of conventional diagnostic pipelines. In addition, we discuss persistent challenges in sample preparation, signal amplification, and system integration, and highlight strategies that couple biochemical amplification with solid‐state electronics to streamline diagnostic workflows. By synthesising the state of the art and identifying critical technological bottlenecks, this review describes the technological progression of next‐generation diagnostic platforms required to accelerate the global elimination of viral hepatitis and to improve patient outcomes through earlier and more equitable access to diagnosis.
- 8 February 2026
- Published by Wiley in Reviews in Medical Virology
- Vol. 36 (2) , e70110
Open AccessAdvances in Rapid Nucleic Acid Diagnostics for Hepatitis B and C Viruses: A Comprehensive Review
Chronic viral hepatitis, predominantly caused by HBV and HCV infections, remains a major global health burden and a leading cause of cirrhosis, hepatocellular carcinoma (HCC), and liver‐related mortality. Achieving the World Health Organisation (WHO) target of diagnosing 90% of HBV and HCV infections by 2030 necessitates a fundamental transition from centralised laboratory‐based testing towards rapid, accessible, and decentralised diagnostic solutions. This review provides a comprehensive and critical assessment of the current diagnostic landscape for viral hepatitis, spanning established commercial assays and emerging nucleic acid testing (NAT) technologies. We systematically examine recent advances in biosensor‐enabled diagnostics, with particular emphasis on the integration of isothermal amplification and CRISPR‐based molecular recognition into electrochemical and field‐effect transistor (FET) platforms. These electronic sensing technologies enable label‐free signal transduction, scalable miniaturisation, and seamless integration with point‐of‐care (POC) workflows, thereby addressing key limitations of conventional diagnostic pipelines. In addition, we discuss persistent challenges in sample preparation, signal amplification, and system integration, and highlight strategies that couple biochemical amplification with solid‐state electronics to streamline diagnostic workflows. By synthesising the state of the art and identifying critical technological bottlenecks, this review describes the technological progression of next‐generation diagnostic platforms required to accelerate the global elimination of viral hepatitis and to improve patient outcomes through earlier and more equitable access to diagnosis.
- Open Access
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , e7366206
Development and Validation of the Steatotic Liver Disease Lab Data Index: A Refined Diagnostic Tool
Aims: Steatotic liver disease (SLD) is highly prevalent, yet large‐scale identification remains challenging because imaging is not always available and existing noninvasive indices perform heterogeneously across subgroups. We developed and validated sex‐ and age‐stratified laboratory‐based indices for simplified SLD identification. Methods: We analyzed 2085 adults from NHANES III (1988–1994). An exposure‐wide association study (EWAS) of 119 clinical features informed sex‐ and age‐stratified logistic models to derive two SLD lab data indices (SLDLD1‐2) and simplified categorical versions (SSLDLD1‐2). Discrimination (AUROC) was compared with FLI, HSI, NAFLD‐LFS, and US‐FLI using paired DeLong tests. Bootstrap internal validation, comparison with a pooled nonstratified model, and decision curve analysis were additionally performed. External validation was performed for SSLDLD1 in NHANES 2017‐2018 and the Taiwan MJ Health database. SLDLD2/SSLDLD2 were not externally validated because C‐peptide was unavailable in both datasets. Results: Central adiposity and insulin‐resistance markers were key predictors, whereas β‐carotene showed an inverse association and contributed to discrimination, particularly in men. Across strata, SLDLD1 achieved AUROCs of 0.71–0.79 in derivation. The stratified framework outperformed a pooled nonstratified model in the overall cohort, in men, and in women aged < 55 years. SLDLD1 also outperformed FLI and HSI across strata and showed superior or comparable performance versus NAFLD‐LFS and US‐FLI, with stratum‐dependent differences. External validation of SSLDLD1 yielded AUROCs of 0.71–0.80 across datasets. Feature‐reduction analysis and an MJ‐variables‐only implementation of SSLDLD1 showed only small absolute AUROC changes overall, supporting simplified implementation when nonroutine biomarkers such as β ‐carotene and insulin are unavailable, although fixed NHANES III‐derived thresholds were not fully transferable to the MJ cohort. Conclusion: The stratified SLDLD framework provides a practical toolbox for SLD identification, supporting high‐throughput research and implementation in settings where advanced imaging is not readily available. SSLDLD1 showed acceptable external discrimination across U.S. and Taiwanese datasets and may be more feasible for settings without nonroutine biomarkers, although local recalibration and validation of decision thresholds are needed before implementation across populations. Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIC, Akaike information criterion; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the receiver‐operating. characteristic curve; BMI, body mass index; CAP, controlled attenuation parameter; CI, confidence interval; CMRF, cardiometabolic risk factor; DM, diabetes mellitus; EWAS, exposure‐wide association study; FLI, fatty liver index; FSI, Framingham steatosis index; FPG, fasting plasma glucose; GGT, gamma‐glutamyl transferase; HbA1c, glycated hemoglobin; HCC, hepatocellular carcinoma; HDL, high‐density lipoprotein; HOMA‐IR, homeostasis model assessment of insulin resistance; HSI, hepatic steatosis index; IR, insulin resistance; LDL, low‐density lipoprotein; MCHC, mean corpuscular hemoglobin concentration; MJ, MJ Health (Taiwan); NAFLD, nonalcoholic fatty liver disease; NAFLD‐LFS, nonalcoholic fatty liver disease liver fat score; NHANES, National Health and Nutrition Examination Survey; NPV, negative predictive value; PPV, positive predictive value; SLD, steatotic liver disease; SLDLD, steatotic liver disease lab data; SLDLD1/SLDLD2, steatotic liver disease lab data indices 1/2; SSLDLD, simplified steatotic liver disease lab data; SSLDLD1/SSLDLD2, simplified steatotic liver disease lab data indices 1/2; TG, triglyceride; US‐FLI, US fatty liver index; VCTE, vibration‐controlled transient elastography; WC, waist circumference; WHR, waist‐to‐hip ratio.
- 1 January 2026
- Published by Wiley in Canadian Journal of Gastroenterology and Hepatology
- Vol. 2026 (1) , e7366206
Open AccessDevelopment and Validation of the Steatotic Liver Disease Lab Data Index: A Refined Diagnostic Tool
Aims: Steatotic liver disease (SLD) is highly prevalent, yet large‐scale identification remains challenging because imaging is not always available and existing noninvasive indices perform heterogeneously across subgroups. We developed and validated sex‐ and age‐stratified laboratory‐based indices for simplified SLD identification. Methods: We analyzed 2085 adults from NHANES III (1988–1994). An exposure‐wide association study (EWAS) of 119 clinical features informed sex‐ and age‐stratified logistic models to derive two SLD lab data indices (SLDLD1‐2) and simplified categorical versions (SSLDLD1‐2). Discrimination (AUROC) was compared with FLI, HSI, NAFLD‐LFS, and US‐FLI using paired DeLong tests. Bootstrap internal validation, comparison with a pooled nonstratified model, and decision curve analysis were additionally performed. External validation was performed for SSLDLD1 in NHANES 2017‐2018 and the Taiwan MJ Health database. SLDLD2/SSLDLD2 were not externally validated because C‐peptide was unavailable in both datasets. Results: Central adiposity and insulin‐resistance markers were key predictors, whereas β‐carotene showed an inverse association and contributed to discrimination, particularly in men. Across strata, SLDLD1 achieved AUROCs of 0.71–0.79 in derivation. The stratified framework outperformed a pooled nonstratified model in the overall cohort, in men, and in women aged < 55 years. SLDLD1 also outperformed FLI and HSI across strata and showed superior or comparable performance versus NAFLD‐LFS and US‐FLI, with stratum‐dependent differences. External validation of SSLDLD1 yielded AUROCs of 0.71–0.80 across datasets. Feature‐reduction analysis and an MJ‐variables‐only implementation of SSLDLD1 showed only small absolute AUROC changes overall, supporting simplified implementation when nonroutine biomarkers such as β ‐carotene and insulin are unavailable, although fixed NHANES III‐derived thresholds were not fully transferable to the MJ cohort. Conclusion: The stratified SLDLD framework provides a practical toolbox for SLD identification, supporting high‐throughput research and implementation in settings where advanced imaging is not readily available. SSLDLD1 showed acceptable external discrimination across U.S. and Taiwanese datasets and may be more feasible for settings without nonroutine biomarkers, although local recalibration and validation of decision thresholds are needed before implementation across populations. Abbreviations: AASLD, American Association for the Study of Liver Diseases; AIC, Akaike information criterion; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; AUROC, area under the receiver‐operating. characteristic curve; BMI, body mass index; CAP, controlled attenuation parameter; CI, confidence interval; CMRF, cardiometabolic risk factor; DM, diabetes mellitus; EWAS, exposure‐wide association study; FLI, fatty liver index; FSI, Framingham steatosis index; FPG, fasting plasma glucose; GGT, gamma‐glutamyl transferase; HbA1c, glycated hemoglobin; HCC, hepatocellular carcinoma; HDL, high‐density lipoprotein; HOMA‐IR, homeostasis model assessment of insulin resistance; HSI, hepatic steatosis index; IR, insulin resistance; LDL, low‐density lipoprotein; MCHC, mean corpuscular hemoglobin concentration; MJ, MJ Health (Taiwan); NAFLD, nonalcoholic fatty liver disease; NAFLD‐LFS, nonalcoholic fatty liver disease liver fat score; NHANES, National Health and Nutrition Examination Survey; NPV, negative predictive value; PPV, positive predictive value; SLD, steatotic liver disease; SLDLD, steatotic liver disease lab data; SLDLD1/SLDLD2, steatotic liver disease lab data indices 1/2; SSLDLD, simplified steatotic liver disease lab data; SSLDLD1/SSLDLD2, simplified steatotic liver disease lab data indices 1/2; TG, triglyceride; US‐FLI, US fatty liver index; VCTE, vibration‐controlled transient elastography; WC, waist circumference; WHR, waist‐to‐hip ratio.
- Open Access
- 12 June 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (7) , 863-864
Response to comment on “Comparison of clinical features and associated comorbidities of vestibular migraine in Taiwan”
- 12 June 2025
- Published by Elsevier in Journal of the Formosan Medical Association
- Vol. 125 (7) , 863-864
Open AccessResponse to comment on “Comparison of clinical features and associated comorbidities of vestibular migraine in Taiwan”
- Open Access
- 13 May 2025
- Published by Elsevier in Journal of the Formosan Medical Association
Comparison of clinical features and associated comorbidities of vestibular migraine in Taiwan
- 13 May 2025
- Published by Elsevier in Journal of the Formosan Medical Association
Open AccessComparison of clinical features and associated comorbidities of vestibular migraine in Taiwan
- Open Access
Patients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate
This study retrospectively analyzed the medical records of 602 patients with first-time positive results for the HCV nucleic acid test between 1 May 2021 and 31 March 2023, exploring the association between DAA treatment and SARS-CoV-2 infection. The results showed that 9.8% of HCV patients were co-infected with SARS-CoV-2. Gender, age, vaccination status, and HCV genotype did not significantly affect SARS-CoV-2 infection. However, patients undergoing DAA treatment showed significantly lower rates of SARS-CoV-2 infection and mortality compared to those not undergoing DAA treatment. The analysis also compared patients undergoing different DAA treatments, with Epclusa and Maviret showing superior protection against SARS-CoV-2. Furthermore, this study explored the severity and mortality of SARS-CoV-2 infection in patients undergoing and having completed DAA treatment. It revealed that patients diagnosed with COVID-19 during DAA treatment experienced only mild symptoms, and none died, suggesting a potential protective effect of DAA treatment against severe outcomes of SARS-CoV-2 infection. The findings contribute to the understanding of the interplay between HCV, DAA treatment, and SARS-CoV-2 infection, highlighting the need for continued monitoring and healthcare measures for individuals with chronic conditions during the ongoing COVID-19 pandemic.
Open AccessPatients with Hepatitis C Undergoing Direct-Acting Antiviral Treatment Have a Lower SARS-CoV-2 Infection Rate
This study retrospectively analyzed the medical records of 602 patients with first-time positive results for the HCV nucleic acid test between 1 May 2021 and 31 March 2023, exploring the association between DAA treatment and SARS-CoV-2 infection. The results showed that 9.8% of HCV patients were co-infected with SARS-CoV-2. Gender, age, vaccination status, and HCV genotype did not significantly affect SARS-CoV-2 infection. However, patients undergoing DAA treatment showed significantly lower rates of SARS-CoV-2 infection and mortality compared to those not undergoing DAA treatment. The analysis also compared patients undergoing different DAA treatments, with Epclusa and Maviret showing superior protection against SARS-CoV-2. Furthermore, this study explored the severity and mortality of SARS-CoV-2 infection in patients undergoing and having completed DAA treatment. It revealed that patients diagnosed with COVID-19 during DAA treatment experienced only mild symptoms, and none died, suggesting a potential protective effect of DAA treatment against severe outcomes of SARS-CoV-2 infection. The findings contribute to the understanding of the interplay between HCV, DAA treatment, and SARS-CoV-2 infection, highlighting the need for continued monitoring and healthcare measures for individuals with chronic conditions during the ongoing COVID-19 pandemic.
- Open Access
- 29 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (19) , 3095
Predictive Value of Clinicopathological Factors to Guide Post-Operative Radiotherapy in Completely Resected pN2-Stage III Non-Small Cell Lung Cancer
Introduction: With the evolution of radiotherapy techniques and a better understanding of clinicopathological factors, we aimed to evaluate the treatment effect of post-operative radiotherapy (PORT) and associated predictive factors in patients with completely resected pN2 stage III non-small cell lung cancer (R0 pN2-stage III NSCLC). Material and Method: The cancer registration database of a single medical center was searched for R0 pN2-stage III NSCLC. Clinicopathological factors and information about post-operative therapies, including PORT and adjuvant systemic treatment, were retrospectively collected and analyzed. The Kaplan-Meier method and a Cox regression model were applied for time-to-event analysis, with disease-free survival (DFS) being the primary outcome. Results: From 2010 to 2021, 82 R0 pN2-stage III NSCLC patients were evaluated, with 70.1% of tumors harboring epidermal growth factor receptor mutations (EGFR mut.). PORT was performed in 73.2% of cases, and the median dose was 54 Gy. After a median follow-up of 42 months, the 3-year DFS and overall survival (OS) rates were 40.6% and 77.3%, respectively. Distant metastasis (DM) was the main failure pattern. In the overall cohort, DFS was improved with PORT (3-year DFS: 44.9% vs. 29.8%; HR: 0.552, p = 0.045). Positive predictive factors for PORT benefit, including EGFR mut., negative extranodal extension, positive lymphovascular invasion, 1–3 positive lymph nodes, and a positive-to-dissected lymph node ratio ≤0.22, were recognized. OS improvement was also observed in subgroups with less lymph node burden. Conclusions: For R0 pN2-stage III NSCLC, PORT prolongs DFS and OS in selected patients. Further studies on predictive factors and the development of nomograms guiding the application of PORT are highly warranted, aiming to enhance the personalization of lung cancer treatment.
- 29 September 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (19) , 3095
Open AccessPredictive Value of Clinicopathological Factors to Guide Post-Operative Radiotherapy in Completely Resected pN2-Stage III Non-Small Cell Lung Cancer
Introduction: With the evolution of radiotherapy techniques and a better understanding of clinicopathological factors, we aimed to evaluate the treatment effect of post-operative radiotherapy (PORT) and associated predictive factors in patients with completely resected pN2 stage III non-small cell lung cancer (R0 pN2-stage III NSCLC). Material and Method: The cancer registration database of a single medical center was searched for R0 pN2-stage III NSCLC. Clinicopathological factors and information about post-operative therapies, including PORT and adjuvant systemic treatment, were retrospectively collected and analyzed. The Kaplan-Meier method and a Cox regression model were applied for time-to-event analysis, with disease-free survival (DFS) being the primary outcome. Results: From 2010 to 2021, 82 R0 pN2-stage III NSCLC patients were evaluated, with 70.1% of tumors harboring epidermal growth factor receptor mutations (EGFR mut.). PORT was performed in 73.2% of cases, and the median dose was 54 Gy. After a median follow-up of 42 months, the 3-year DFS and overall survival (OS) rates were 40.6% and 77.3%, respectively. Distant metastasis (DM) was the main failure pattern. In the overall cohort, DFS was improved with PORT (3-year DFS: 44.9% vs. 29.8%; HR: 0.552, p = 0.045). Positive predictive factors for PORT benefit, including EGFR mut., negative extranodal extension, positive lymphovascular invasion, 1–3 positive lymph nodes, and a positive-to-dissected lymph node ratio ≤0.22, were recognized. OS improvement was also observed in subgroups with less lymph node burden. Conclusions: For R0 pN2-stage III NSCLC, PORT prolongs DFS and OS in selected patients. Further studies on predictive factors and the development of nomograms guiding the application of PORT are highly warranted, aiming to enhance the personalization of lung cancer treatment.
- 20 May 2023
- Published by Wiley in Transfusion Medicine
- Vol. 33 (4) , 320-328
Trend in seroprevalence of HTLV‐1/2 in Taiwanese blood donors—A 10‐year follow‐up
Objectives: This study evaluated the Human T-lymphotropic virus (HTLV) screening policy impact on the HTLV seroprevalence from 2009 to 2018 as well as the differences between administrative districts in terms of prevalence distribution in Taiwan.Background: Since February 1996, the Taiwan Blood Services Foundation (TBSF) had conducted HTLV screening of blood donors. The HTLV seroprevalence was 0.032% in 1999.Materials and Methods: This cross-sectional study included donors' data collected from blood donation centres across Taiwan from 2009 to 2018. Enzyme immunoassay and Western blot assay were used for screening and confirmation of HTLV infections. In this study, the researchers calculated the trends in the HTLV rates of first-time and repeat donors across time as well as the HTLV prevalence distribution across the 22 administrative districts of Taiwan.Results: Amongst 17 977 429 employed blood donations, 739 HTLV-seropositive donations (4.11 per 100 000 donations) were identified. The HTLV-positive donors were aged between 17 and 64 years, with a median age of 49 years. The overall seropositivity rates of first-time and repeat donors were 34.36/100 000 and 1.27/100 000. HTLV seroprevalence in first-time blood donors significantly decreased by 57% (crude odds ratio [95% confidence interval] (crude OR [95% CI]) = 0.43 [0.28-0.64]) within 10 years. A slight decline was also identified in repeat donors (crude OR [95% CI] = 0.73 [0.4-1.32]). Donors from different districts showed significantly varied prevalence. Most districts with high prevalence are situated in eastern Taiwan, for both donation types. Older blood donors were more likely to be infected with HTLV than younger ones in first time and repeat donors. Middle age donors (50-65 years) had an 18.47-39.65 greater risk than those aged <20 years. Significant higher risk of female was observed in both donation types. Amongst different age groups, first-time female donors increase 1.31-1.88 times infection risk and female in repeat donor group had 1.55-3.43 times greater risk.Conclusion: Over years of implementation of the HTLV blood donor screening policy by the TBSF, the HTLV seroprevalence of first-time donors has decreased consistently. Moreover, the HTLV seroprevalence of repeat donors has dropped considerably. This implies that the screening policy provides continued benefit. Females and older blood donors were more likely infected with HTLV than males and younger blood donors. The influence of age on infection was greater amongst first-time donors than amongst repeat donors. Therefore, appropriate measures should be taken to ensure public safety.
- 20 May 2023
- Published by Wiley in Transfusion Medicine
- Vol. 33 (4) , 320-328
Trend in seroprevalence of HTLV‐1/2 in Taiwanese blood donors—A 10‐year follow‐up
Objectives: This study evaluated the Human T-lymphotropic virus (HTLV) screening policy impact on the HTLV seroprevalence from 2009 to 2018 as well as the differences between administrative districts in terms of prevalence distribution in Taiwan.Background: Since February 1996, the Taiwan Blood Services Foundation (TBSF) had conducted HTLV screening of blood donors. The HTLV seroprevalence was 0.032% in 1999.Materials and Methods: This cross-sectional study included donors' data collected from blood donation centres across Taiwan from 2009 to 2018. Enzyme immunoassay and Western blot assay were used for screening and confirmation of HTLV infections. In this study, the researchers calculated the trends in the HTLV rates of first-time and repeat donors across time as well as the HTLV prevalence distribution across the 22 administrative districts of Taiwan.Results: Amongst 17 977 429 employed blood donations, 739 HTLV-seropositive donations (4.11 per 100 000 donations) were identified. The HTLV-positive donors were aged between 17 and 64 years, with a median age of 49 years. The overall seropositivity rates of first-time and repeat donors were 34.36/100 000 and 1.27/100 000. HTLV seroprevalence in first-time blood donors significantly decreased by 57% (crude odds ratio [95% confidence interval] (crude OR [95% CI]) = 0.43 [0.28-0.64]) within 10 years. A slight decline was also identified in repeat donors (crude OR [95% CI] = 0.73 [0.4-1.32]). Donors from different districts showed significantly varied prevalence. Most districts with high prevalence are situated in eastern Taiwan, for both donation types. Older blood donors were more likely to be infected with HTLV than younger ones in first time and repeat donors. Middle age donors (50-65 years) had an 18.47-39.65 greater risk than those aged <20 years. Significant higher risk of female was observed in both donation types. Amongst different age groups, first-time female donors increase 1.31-1.88 times infection risk and female in repeat donor group had 1.55-3.43 times greater risk.Conclusion: Over years of implementation of the HTLV blood donor screening policy by the TBSF, the HTLV seroprevalence of first-time donors has decreased consistently. Moreover, the HTLV seroprevalence of repeat donors has dropped considerably. This implies that the screening policy provides continued benefit. Females and older blood donors were more likely infected with HTLV than males and younger blood donors. The influence of age on infection was greater amongst first-time donors than amongst repeat donors. Therefore, appropriate measures should be taken to ensure public safety.
- Open Access
Using Real-Time PCR Fluorescence Reaction Values to Improve SARS-CoV-2 Virus Detection and Benefit Clinical Decision-Making
This study aimed to compare the SARS-CoV-2 nucleic acid detection results of the BD MAX™ System and other platforms to formulate an optimized laboratory verification process. The re-examination of 400 samples determined as positive by BD MAX™ indicated that the inconsistency rate between BD MAX™ and the other platforms was 65.8%; the inconsistency rate of single-gene-positive results was as high as 99.2%. A receiver operating characteristic curve was drawn for the relative light unit (RLU) values of samples positive for a single gene, and RLU 800 was used as the cutoff. After setting the retest standard as single-gene positive and RLU ≥ 800, the number of the 260 BD MAX™ single-gene positives that needed to be confirmed again was 36 (13.8%) and the number that could be directly reported as negative was 224 (86.2%). This verification process can shorten the reporting period and speed up the epidemic adjustment time and turnover rate of special wards, thereby improving SARS-CoV-2 detection efficiency and clinical decision-making.
Open AccessUsing Real-Time PCR Fluorescence Reaction Values to Improve SARS-CoV-2 Virus Detection and Benefit Clinical Decision-Making
This study aimed to compare the SARS-CoV-2 nucleic acid detection results of the BD MAX™ System and other platforms to formulate an optimized laboratory verification process. The re-examination of 400 samples determined as positive by BD MAX™ indicated that the inconsistency rate between BD MAX™ and the other platforms was 65.8%; the inconsistency rate of single-gene-positive results was as high as 99.2%. A receiver operating characteristic curve was drawn for the relative light unit (RLU) values of samples positive for a single gene, and RLU 800 was used as the cutoff. After setting the retest standard as single-gene positive and RLU ≥ 800, the number of the 260 BD MAX™ single-gene positives that needed to be confirmed again was 36 (13.8%) and the number that could be directly reported as negative was 224 (86.2%). This verification process can shorten the reporting period and speed up the epidemic adjustment time and turnover rate of special wards, thereby improving SARS-CoV-2 detection efficiency and clinical decision-making.
- Open Access
- 26 October 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (30) , 10896-10905
Prevalence and risk factors for Candida esophagitis among human immunodeficiency virus-negative individuals
Candida esophagitis (CE) is among the commonest esophageal infections and is known as an opportunistic fungal infection mostly affecting people living with the human immunodeficiency virus (HIV). However, some medical conditions might predispose HIV-negative individuals to esophageal candidiasis. The epidemio logy and associated endoscopic findings of CE among people without HIV have rarely been reported. To investigate the prevalence of CE among HIV-negative persons, and determine risk factors predicting CE. Between January 2015 and December 2018, all consecutive outpatients who under went routine esophagogastroduodenoscopy as part of health check-ups at their own expense at the Health Check-up Center of the Kaohsiung Veterans General Hospital, Taiwan, were recruited in this study. Those with positive HIV serology results were excluded. Sociodemographic and clinical characteristics including age, gender, economic status, smoking history, alcohol consumption, tea and coffee consumption, underlying diseases, body fat percentage, body mass index, endoscopic findings, and Helicobacter pylori infection status were carefully reviewed. CE was confirmed by endoscopic biopsy and pathological assessment with hematoxylin and eosin and periodic acid-Schiff staining. To evaluate independent factors predicting the development of CE, we conducted a univariate analysis of clinical characteristics. The variables found to be significant via univariate analysis were subsequently included in a multivariable analysis of potential risk factors for CE development. A total of 11802 participants were included in this study. Forty-seven (0.4%) were confirmed as having CE by pathological examination. Univariate analysis identified older age, the presence of chronic kidney disease, alcohol consumption, and steroid use (P = 0.023, < 0.001, 0.033, and 0.004, respectively) as significantly associated with CE. Multivariable analysis revealed older age [adjusted odds ratio (OR) = 1.027; 95%CI: 1.001-1.053; P = 0.045], chronic kidney disease (adjusted OR = 13.470; 95%CI: 4.574-39.673; P < 0.001), alcohol consumption (adjusted OR = 2.103; 95%CI: 1.151-3.844; P = 0.016), and steroid use (adjusted OR = 24.255; 95%CI: 5.343-110.115; P < 0.001) as independent risk factors for CE development. The presence of dysphagia was associated with severe CE (P = 0.021). The prevalence of CE among HIV-negative persons was 0.4% in Taiwan. Independent risk factors for CE were older age, chronic kidney disease, alcohol consumption, and steroid use.
- 26 October 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 10 (30) , 10896-10905
Open AccessPrevalence and risk factors for Candida esophagitis among human immunodeficiency virus-negative individuals
Candida esophagitis (CE) is among the commonest esophageal infections and is known as an opportunistic fungal infection mostly affecting people living with the human immunodeficiency virus (HIV). However, some medical conditions might predispose HIV-negative individuals to esophageal candidiasis. The epidemio logy and associated endoscopic findings of CE among people without HIV have rarely been reported. To investigate the prevalence of CE among HIV-negative persons, and determine risk factors predicting CE. Between January 2015 and December 2018, all consecutive outpatients who under went routine esophagogastroduodenoscopy as part of health check-ups at their own expense at the Health Check-up Center of the Kaohsiung Veterans General Hospital, Taiwan, were recruited in this study. Those with positive HIV serology results were excluded. Sociodemographic and clinical characteristics including age, gender, economic status, smoking history, alcohol consumption, tea and coffee consumption, underlying diseases, body fat percentage, body mass index, endoscopic findings, and Helicobacter pylori infection status were carefully reviewed. CE was confirmed by endoscopic biopsy and pathological assessment with hematoxylin and eosin and periodic acid-Schiff staining. To evaluate independent factors predicting the development of CE, we conducted a univariate analysis of clinical characteristics. The variables found to be significant via univariate analysis were subsequently included in a multivariable analysis of potential risk factors for CE development. A total of 11802 participants were included in this study. Forty-seven (0.4%) were confirmed as having CE by pathological examination. Univariate analysis identified older age, the presence of chronic kidney disease, alcohol consumption, and steroid use (P = 0.023, < 0.001, 0.033, and 0.004, respectively) as significantly associated with CE. Multivariable analysis revealed older age [adjusted odds ratio (OR) = 1.027; 95%CI: 1.001-1.053; P = 0.045], chronic kidney disease (adjusted OR = 13.470; 95%CI: 4.574-39.673; P < 0.001), alcohol consumption (adjusted OR = 2.103; 95%CI: 1.151-3.844; P = 0.016), and steroid use (adjusted OR = 24.255; 95%CI: 5.343-110.115; P < 0.001) as independent risk factors for CE development. The presence of dysphagia was associated with severe CE (P = 0.021). The prevalence of CE among HIV-negative persons was 0.4% in Taiwan. Independent risk factors for CE were older age, chronic kidney disease, alcohol consumption, and steroid use.
- Open Access
- 16 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (37) , e30412
Recurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis
Venous thromboembolism (VTE) is associated with a high risk of morbidity and mortality. However, data on the association between oral anticoagulants and the hazards of VTE complications in Taiwanese patients with VTE is limited. This study aimed to compare the hazards of recurrent VTE, bleeding, and mortality between patients with VTE receiving rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), and those receiving heparin or low-molecular-weight heparin (LMWH) followed by warfarin. Patients with VTE treated with rivaroxaban, or heparin or LMWH followed by warfarin were enrolled from 2 million random samples from Taiwan’s National Health Insurance database between 2013 and 2016. Hazards of recurrent VTE (deep vein thrombosis and pulmonary embolism), major bleeding, and mortality in rivaroxaban and warfarin users were investigated. Survival analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Users of rivaroxaban (183) and warfarin (456) were included in the study. Patients receiving rivaroxaban did not have significantly lower hazards of developing recurrent VTE (HR, 0.72 [CI, 0.37–1.37], P = .31) and mortality (HR, 0.86 [CI, 0.49–1.50], P = .59) than those receiving heparin or LMWH followed by warfarin. In addition, the hazard ratio of major bleeding was not significantly different between the 2 regimens (HR, 1.80 [CI, 0.39–8.29], P = .45). Rivaroxaban was not associated with lower risks of recurrent VTE and mortality and higher hazards of major bleeding than heparin or LMWH followed by warfarin in Taiwanese patients with VTE. Clinicians may tailor oral anticoagulants for VTE patients according to the patient’s characteristics, cost-effectiveness and healthcare system policy.
- 16 September 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (37) , e30412
Open AccessRecurrent thromboembolism, bleeding, and mortality in Asian patients with venous thromboembolism receiving different oral anticoagulants: A nationwide analysis
Venous thromboembolism (VTE) is associated with a high risk of morbidity and mortality. However, data on the association between oral anticoagulants and the hazards of VTE complications in Taiwanese patients with VTE is limited. This study aimed to compare the hazards of recurrent VTE, bleeding, and mortality between patients with VTE receiving rivaroxaban, a non-vitamin K antagonist oral anticoagulant (NOAC), and those receiving heparin or low-molecular-weight heparin (LMWH) followed by warfarin. Patients with VTE treated with rivaroxaban, or heparin or LMWH followed by warfarin were enrolled from 2 million random samples from Taiwan’s National Health Insurance database between 2013 and 2016. Hazards of recurrent VTE (deep vein thrombosis and pulmonary embolism), major bleeding, and mortality in rivaroxaban and warfarin users were investigated. Survival analyses were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Users of rivaroxaban (183) and warfarin (456) were included in the study. Patients receiving rivaroxaban did not have significantly lower hazards of developing recurrent VTE (HR, 0.72 [CI, 0.37–1.37], P = .31) and mortality (HR, 0.86 [CI, 0.49–1.50], P = .59) than those receiving heparin or LMWH followed by warfarin. In addition, the hazard ratio of major bleeding was not significantly different between the 2 regimens (HR, 1.80 [CI, 0.39–8.29], P = .45). Rivaroxaban was not associated with lower risks of recurrent VTE and mortality and higher hazards of major bleeding than heparin or LMWH followed by warfarin in Taiwanese patients with VTE. Clinicians may tailor oral anticoagulants for VTE patients according to the patient’s characteristics, cost-effectiveness and healthcare system policy.